First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors.
首次人体 I/Ib 期研究，评估 NIZ985（IL-15 和 IL-15Rα 的重组异二聚体）作为单药以及与 spartalizumab 联合治疗晚期和转移性实体瘤患者的疗效
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2023-007725
Leidner Rom, Conlon Kevin, McNeel Douglas G, Wang-Gillam Andrea, Gupta Sumati, Wesolowski Robert, Chaudhari Monica, Hassounah Nadia, Lee Jong Bong, Ho Lee Lang, O'Keeffe Jessica A, Lewis Nancy, Pavlakis George N, Thompson John A
